Baird analyst Wesley Golladay upgrades Regency Centers (NASDAQ:REG) from Neutral to Outperform and announces $71 price target.
Opthea’s Phase 2B Results Of OPT-302, Anti-VEGF-C/-D “Trap” Agent Administered In Combination With Lucentis (Ranibizumab) For Wet Age-Related Macular Degeneration Have Been Published In Ophthalmology, Journal Of The American Academy Ophthalmology
The prospective, randomized, controlled Phase 2b trial of 366 treatment-naïve patients with wet AMD, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the
